Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Fomivirsen sodium; ISIS 2922; Vitravene

Latest Information Update: 16 Jan 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Isis Pharmaceuticals
  • Developer Isis Pharmaceuticals; Pacira Pharmaceuticals
  • Class Antisense oligonucleotides; Antivirals; Thionucleotides
  • Mechanism of Action RNA binding protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cytomegalovirus infections
  • New Molecular Entity Yes

Highest Development Phases

  • Market Withdrawal Cytomegalovirus infections

Most Recent Events

  • 11 Jan 2016 Ionis Pharmaceuticals completes a phase I/II trial in Cytomegalovirus infections in USA (Ophthalmic) before June 2005 (NCT00002187)
  • 18 Nov 2005 Fomivirsen has received Orphan Drug Status for CMV-induced retinitis in AIDS patients in Australia
  • 30 Jul 2002 Withdrawn for Cytomegalovirus infections in European Union (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top